Aims: To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin.
| INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a progressive disease, for which many patients require combination therapy to maintain glycaemic control over time. 1 Metformin is the standard first-line pharmacotherapy for the treatment of T2DM, unless it is contra-indicated or not tolerated. 1 Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, are commonly used as second-line therapy and exert an antihyperglycaemic effect by increasing concentrations of incretin hormones, thereby enhancing insulin secretion. 2, 3 While the combination of metformin and sitagliptin has been shown to provide good glycaemic efficacy, 4, 5 as the disease progresses and glycaemic control declines, some patients may benefit from the addition of a third agent with a complementary mode of action.
1 Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent the latest class of agents approved for the treatment of T2DM. 6, 7 They have an insulin-independent mode of action and inhibit renal glucose reabsorption, resulting in enhanced urinary glucose excretion and thereby reducing plasma glucose and glycated haemoglobin (HbA1c)
concentrations. SGLT2 inhibitors have also been shown to reduce body weight and blood pressure (BP) 7 and are generally well-tolerated, with a low risk of hypoglycaemia.
Combination therapy with an SGLT2 inhibitor and a DPP-4 inhibitor offers 2 antihyperglycaemic agents with different, complementary mechanisms of action. 2, 3 Furthermore, it has been hypothesized that DPP-4 inhibitors may offset the increase in the rate of endogenous glucose production induced by SGLT2 inhibitors, potentially leading to additive effects on HbA1c reduction. 8 Ertugliflozin is a highly selective SGLT2 inhibitor currently being evaluated in the VERTIS (eValuation of ERTugliflozin effIcacy and Safety) clinical trial programme. Two doses of ertugliflozin (5 and 15 mg once daily [QD] ) were selected for Phase 3 studies, as these doses were predicted to provide >80% and >90% of maximal pharmacology for urinary glucose excretion and glycaemic (HbA1c, fasting plasma glucose [FPG] ) and body weight endpoints based on Phase 2 studies. 9, 10 The aim of this study (VERTIS SITA2) was to compare the safety and efficacy of the addition of ertugliflozin (5 and 15 mg QD) to that of placebo in patients with T2DM and inadequate glycaemic control while receiving a combination of metformin and sitagliptin.
| MATERIAL AND METHODS

| Study design
Protocol MK-8835-006 was a randomized, double-blind, placebocontrolled, parallel-group Phase 3 study (ClinicalTrials.gov identifier: NCT02036515). It was conducted over 52 weeks in 2 phases; the primary time point was at Week 26 (Phase A) and treatment was continued into a 26-week extension (Phase B).
The trial was conducted at 104 centres across 12 countries (Appendix S1 Sitting BP was measured in triplicate using an automated oscillometric BP measuring device. HOMA-β was calculated using FPG and fasting C-peptide levels, which were measured at baseline, Weeks 26 and 52, using the calculator released by the University of Oxford in 2004. 13 The EQ-5D-3L assessment was performed at baseline, and at Weeks 26 and 52. Orthostatic BP (defined in Appendix S1) was assessed at baseline, Weeks 6 and 26.
| Safety assessments
| Statistical analyses
A planned sample size of approximately 405 patients (135 patients per group) was estimated to provide 97% power to detect a true difference of 0.5% in the mean change from baseline in HbA1c between a given ertugliflozin dose and placebo, based on a 2-sided test at 5% level of significance, assuming approximately 19% attrition at Week 26, and assuming a standard deviation of 1.0.
Primary and key secondary efficacy endpoints were tested at Week 26 in the following order: HbA1c, FPG, body weight, proportion of patients with HbA1c <7.0% (53 mmol/mol) and SBP. For each endpoint, the 15-mg dose was tested vs placebo, followed by the 5-mg dose vs placebo. Each test was performed at the 0.05 level, and testing continued until a P value ≥.05 was obtained.
Efficacy analyses included all randomized patients who received ≥1
dose of study drug and had ≥1 measurement of the respective endpoint.
Post-rescue efficacy data were treated as missing in all efficacy analyses.
A longitudinal data analysis (LDA) model 14 imputation using the LDA model described above.
In a prespecified analysis, HbA1c reduction from baseline at Week 26 was assessed in the subgroups shown in Table S1 (Appendix S1)
using a repeated measures analysis of covariance model. between-group differences in pre-specified AEs were computed using the Miettinen and Nurminen method. 15 LDL-C and HDL-C were assessed by an LDA model similar to that used for the primary endpoint. Changes from baseline in eGFR and other safety endpoints were summarized descriptively.
3 | RESULTS
| Patient disposition and baseline characteristics
In total, 464 patients were randomized and 462 were analyzed (two patients in the ertugliflozin 15 mg group did not receive study medication) ( Figure S1 , Appendix S1). Baseline demographics were generally similar between groups (Table 1) , except for a higher proportion of males in the placebo group vs ertugliflozin groups. The mean age was 59.1 years; 72.9% of patients were White and 20.3% were Asian. The overall median metformin dose at baseline was 2000 mg/d.
| Efficacy
At respectively; P <.001 for both comparisons) ( Table 2 ; Figure 1A ). At Week 26, HbA1c reductions were greater in the ertugliflozin groups relative to the placebo group across all HbA1c subgroup categories (Table S1 , Appendix S1). Larger placebo-adjusted reductions in HbA1c were observed in those with higher than median baseline A higher proportion of ertugliflozin-treated patients had HbA1c
<7.0% (53 mmol/mol) at Week 26 compared to the placebo group (Table 3 ). The odds of having HbA1c <7.0% (53 mmol/mol) at Week 26 were significantly greater in the ertugliflozin groups vs the placebo group (both P < .001) ( Table 3 ; Figure 1B ).
Significantly greater reductions from baseline were observed at Week 26 for ertugliflozin 5 mg and 15 mg compared to placebo in the key secondary endpoints of FPG, body weight and SBP (Table 3 ; Figure 1C -E). DBP was not prespecified as a key secondary endpoint;
placebo-adjusted reductions in DBP of 1.2 and 1.4 mm Hg were observed in the ertugliflozin 5 mg and 15 mg groups, respectively (Table S2 , Appendix S1). Across treatment groups, the proportion of patients receiving BP-lowering medication did not change in a meaningful manner during the study (Table S3 , Appendix S1).
The effects of ertugliflozin on HbA1c, FPG, body weight and SBP at Week 26 were sustained through Week 52 (Figure 1 ). Fewer ertugliflozin-treated patients received glycaemic rescue medication at or before Week 26 (1.3% and 2.0% in the ertugliflozin 5 mg and ertugliflozin 15 mg groups, respectively) compared with the placebo group (16.3%; nominal P < .001 for both comparisons) (Table S2 , Appendix S1). A similar trend was observed at Week 52 (Table S2 , Appendix S1).
LS mean increases from baseline in HOMA-β (%) at Week 26 were greater in the ertugliflozin 5 and 15 mg groups than in the placebo group, with the improvement in HOMA-β lasting to Week 52 (nominal P < .001
for both comparisons) (Table S2 , Appendix S1). The mean change from baseline in EQ-5D-3L score was negligible in all groups (data not shown).
| Safety
The proportion of patients with 1 or more AEs was similar across groups ( Table 4 ). The incidence of serious AEs and AEs leading to Adjusted odds ratio relative to placebo (95% CI) Genital mycotic infections were more common among male and female patients who received ertugliflozin than among those who received placebo (Table 4 ). The incidence of urinary tract infections was low and not meaningfully different between treatment groups (Table 4 ). The incidence of symptomatic hypoglycaemia (Table 4) 9.9) for ertugliflozin 5 mg and ertugliflozin 15 mg, respectively. Small increases from baseline in HDL-C were observed across all groups; these were higher in the ertugliflozin groups vs the placebo group (Table S5, Ertugliflozin monotherapy improves HOMA-β, a marker of β-cell function. 17 In this study, improvements were also observed despite the fact that patients were already receiving sitagliptin, which is known to improve β-cell function. 23 This is likely to be an indirect therefore, in patients with impaired renal function, the glycaemic efficacy of SGLT2 inhibitors is likely to be attenuated, although beneficial effects on body weight and BP have been observed. [24] [25] [26] [27] Addition of ertugliflozin 5 mg and 15 mg to metformin and sitagliptin was generally well-tolerated over 52 weeks of treatment; no clinically important differences were observed between the two ertugliflozin doses. A higher incidence of genital mycotic infections, a known class effect of SGLT2 inhibitors, 28 was observed in male and female patients receiving ertugliflozin vs placebo. The low incidence of hypoglycaemia in this study is consistent with the mechanism of action of SGLT2 inhibitors. 6, 28 This, together with their mechanism of action which is complementary to that of DPP-4 inhibitors, makes SGLT2 inhibitors an attractive alternative to sulphonylureas for combination therapy.
Treatment with SGLT2 inhibitors causes osmotic diuresis, which may lead to AEs related to volume depletion; 6,29 however, the incidence of hypovolaemia and orthostatic hypotension was low in this study. The risk of volume depletion with an SGLT2 inhibitor is increased in those with moderate renal impairment, advanced age and use of diuretics. In this study, 21.4% of patients reported concomitant diuretic use, and 29.9% were 65 years of age or older. Because of the small sample size of patients using diuretics, as well as the low incidence of hypovolaemia/orthostatic hypotension, the interaction between the two could not be investigated in the present study.
The transient decreases in eGFR observed in this study have been reported with other SGLT2 inhibitors and are probably haemodynamically mediated. 6 Recent evidence suggests that SGLT2 inhibitors may have long-term beneficial effects on renal outcomes, 30 which is probably the result of several direct and indirect effects on the kidney through tubuloglomerular feedback and improvements in hyperglycaemia, hypertension, obesity and hyperuricaemia. 31, 32 In summary, in patients with T2DM who had inadequate glycaemic control with metformin and sitagliptin, the addition of ertugliflozin provided clinically meaningful and durable glycaemic control and reductions in body weight and SBP. Ertugliflozin was generally well-tolerated without a meaningful difference in symptomatic hypoglycaemia, urinary tract infection or hypovolaemia AEs, but resulted in a higher incidence of genital mycotic infections in men and women compared to placebo. 
ACKNOWLEDGMENTS
Author contributions
The authors are responsible for the work described in this paper. 
